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To establish a satisfactory delivery system for the delivery of salinomycin (Sal), a novel, selective cancer stem
cell inhibitor with prominent toxicity, gelatinase-responsive core-shell nanoparticles (NPs), were prepared by
nanoprecipitation method (NR-NPs) and single emulsion method (SE-NPs). The gelatinase-responsive copolymer
was prepared by carboxylation and double amination method. We studied the stability of NPs prepared by
nanoprecipitation method with different proportions of F68 in aqueous phase to determine the best proportion
used in our study. Then, the NPs were prepared by nanoprecipitation method with the best proportion of F68
and single emulsion method, and their physiochemical traits including morphology, particle size, zeta potential,
drug loading content, stability, and in vitro release profiles were studied. The SE-NPs showed significant
differences in particle size, drug loading content, stability, and in vitro release profiles compared to NR-NPs. The SE-NPs
presented higher drug entrapment efficiency and superior stability than the NR-NPs. The drug release rate of
SE-NPs was more sustainable than that of the NR-NPs, and in vivo experiment indicated that NPs could
prominently reduce the toxicity of Sal. Our study demonstrates that the SE-NPs could be a satisfactory method
for the preparation of gelatinase-responsive NPs for intelligent delivery of Sal.
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NanoparticlesBackground
Cancer stem cells (CSCs) represent a small proportion of
cancer cells that exist in the cancer cell population, which
drives tumor growth and recurrence [1,2]. And CSCs are
found to be resistant to conventional cancer treatments,
including chemotherapy and radiotherapy [3-6], which
suggests that many cancer therapies, though killing bulks
of tumor cells, may ultimately fail because they do not
eliminate CSCs, which survive to regenerate new tumors.
Alternatively, tumor drug-resistant cells induced by trad-
itional chemotherapeutics also present cancer stem-like
characteristics [7]. Therefore, novel therapeutic strategies
specifically targeting CSCs are urgently needed.* Correspondence: lirutian@gmail.com; lifengwang@nju.edu.cn
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in any medium, provided the original work is pSalinomycin (Sal) was originally used to kill bacteria,
fungi, and parasites [8]. In 2009, Gupta et al. identified Sal
by a high-throughput screening that could potentially be
used to target breast CSCs, and it killed breast CSCs at least
100 times more effectively than paclitaxel in mice [9]. Since
then, large amounts of studies have been conducted and in-
dicated that Sal can effectively kill various types of cancer
stem-like cells, for instance, colorectal cancer, pancreatic
cancer, prostate cancer, and so on [10-12]. Thus, it is con-
sidered to be a potential anticancer drug for cancer therapy.
However, for several reasons, Sal has never been established
as a drug for human diseases until now. For example,
owing to its poor aqueous solubility, it could not be admin-
istered by intraperitoneal injection without the aid of etha-
nol [13]. In particular, several reports and studies published
in the last three decades revealed a considerable toxicity of
Sal in different kinds of mammals including humans after
accidental oral or inhalative intake [14-17]. To solve thesen Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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used are nanoparticles (NPs) due to their satisfying traits.
Amphiphilic copolymer NPs consisting of hydrophilic
and hydrophobic segments have drawn intensive attention
in antitumor drug delivery systems since the 1990s [18-20].
They present unique characteristics as drug carriers includ-
ing high drug encapsulation efficiency due to optimized
drug solubility in the core [21], preferential accumulation
in tumor tissue via enhanced permeation and retention
(EPR) effect [22,23], the ability to prolong drug release [24]
because of the protection of the drug against chemical and
enzymatic degradation [25], and the capacity to reduce the
systemic adverse effects and the risks of toxicity [26,27]
with the purpose of minimizing the number of administra-
tions for a better patient compliance [28]. Progress in this
field has made it possible for NPs being able to deliver the
drugs to the targeted tumor sites [29-31], which can in-
crease the drug concentration in the tumor region and
reduce the drug content in the normal region. This charac-
teristic can reduce the side effects of the drugs to a large
extent. In the present work, the intelligent gelatinase-
stimuli NPs which are modified by inserting the optimal
gelatinase-cleavable peptide (PVGLIG) between polyethyl-
ene glycol (mPEG) and polycaprolactone (PCL) segment
(mPEG-Pep-PCL) [32] were set up to deliver Sal. Owing to
their special structures, the NPs prepared from mPEG-
Pep-PCL have their own characteristics, such as prolonged
circulating time and accumulation in the tumor site by the
EPR effect [33-35]. Since the gelatinases are known to be
abundantly present in most tumors, once the NPs accumu-
late in the tumors, the mPEG-PCL conjugates will be
cleaved at the certain site of the peptide which results in
the dePEGylated NPs being retained in the tumor regions,
effectively interacting with more tumor cells, increasing
cellular uptake of NPs into cancer cells, and improving
intracellular anticancer drug concentration.
By encapsulating Sal into the PEG-Pep-PCL NPs that
are based on biodegradable polymers, its side effects can
be reduced because of the EPR effects of copolymeric NPs,
sustained release pattern, and gelatinase-triggered drug
targeting. NPs can be formulated by using different prepar-
ation methods [36]. However, few studies have been done
to evaluate the satisfying preparation method for Sal deliv-
ery by NPs. Thus, the aims of this work are to emphasize
the relationship among the particle elaboration process,
the nature of the particles, their size stability, and the en-
capsulated drug release and to choose the optimized way
for Sal delivery. In our study, we confirmed the optimum
preparation method for Sal-loaded NP preparation.
Methods
Synthesis of PEG-peptide conjugates
Two-hundred milligrams of methoxy-polyethylene glycol-
NHS (mPEG-NHS, Jiankai Technology Co., Ltd., Beijing,China) and 26 mg of PVGLIG (HD Biosciences Co., Shanghai,
China) were dissolved in 3 mL of dimethyl formamide
(DMF) containing 3% triethylamine (Et3N) and stirred
for 3 h at room temperature to prepare PEG-peptide
conjugates. The unconjugated peptides were removed by
dialysis in a 3,500-Da MWCO membrane (Greenbird,
Shanghai, China) against deionized water for 24 h.
Synthesis of PCL-COOH copolymers
The dichloromethane (DCM)-dissolved PCL (Mn13800,
determined by proton nuclear magnetic resonance (1H
NMR)) polymers were added with succinic anhydride, 4-
dimethylamiopryidine (DMAP), and pyridine and then
stirred at room temperature for 48 h. The resultant mix-
ture was precipitated in ethyl ether and washed three
times with methanol and then dried under vacuum to
prepare the PCL-COOH.
Synthesis of PCL-NH2 copolymers
The DMF-dissolved PCL-COOH polymers were added
with DMAP, 1-ethyl-3-[3-dimethylaminopropyl] carbodi-
mide hydrochloride (EDC), ethylenediamine and N-hydro-
xysulfosuccinimide sodium salt (NHS), and stirred at 37°C
for 18 h. The mixture was precipitated in ethanol and
dried under vacuum to prepare the PCL-NH2.
Synthesis of PEG-Pep-PCL and PEG-PCL copolymers
The mixture of PCL-NH2 (0.002 mol), PEG-peptide con-
jugates (0.002 mol), DMAP (0.003 mol), EDC (0.002 mol),
and NHS (0.002 mol) in DMF was stirred for 24 h at 32°C.
The crude PEG-peptide-PCL copolymers were purified by
dialysis (MWCO 13 kDa) for 24 h, lyophilized to powder,
and stored at 4°C for further use.
Nanoprecipitation method with different proportions of
poloxamer 188 (F68) in deionized water (aqueous phase)
Different concentrations of surfactants were designed to
select the optimal formulation, which could have long-
term stability. Briefly, 5 mg of PEG-Pep-PCL copoly-
mers was dissolved in 200 μL acetone, and then, the
mixed solution was slowly added to five aqueous solu-
tions (5 mL each) containing 0.125%, 0.25%, 0.5%, and
1.0% (w/w) F68 with quick stirring. The NPs formed and
the solution turned to blue immediately. The remaining
acetone was removed by rotary vacuum evaporation and
the resulting solution was filtered to remove nonincor-
porated drugs.
Sal NPs and blank NPs prepared by nanoprecipitation
method with the best proportion of F68
After the optimal surfactant concentration had been de-
termined, 5 mg of copolymer and 0.5 mg of Sal (China
Institute of Veterinary Drug Control, Beijing, China)
were dissolved in 200 μL acetone, and the mixture was
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proportion of F68 with quick stirring. The NPs formed
and the solution turned to blue immediately. The
remaining acetone was removed by rotary vacuum evap-
oration and the resulting solution was filtered to remove
nonincorporated drugs. The blank NPs were produced
in the same manner without adding Sal.
Single emulsion method
The NPs loaded with Sal were prepared by a modified sin-
gle emulsion method. Briefly, 20 mg of each copolymer
and 2 mg Sal were dissolved in 1 mL of DCM. The mixture
was emulsified in 3 mL of aqueous polyvinyl alcohol (PVA)
solution at 3% (w/v) by sonication (XL2000, Misonix,
Farmingdale, NY, USA) for 60 s (4 W) to obtain an o/w
emulsion. This emulsion was then emulsified in 5 mL of
aqueous solution containing 0.5% (w/v) PVA by sonication
(XL2000, Misonix, USA) for 10 s (2.5 W). The w/o/w
emulsion formed was gently stirred at room temperature in
a fume hood until the evaporation of the organic solvent
was complete. The resulting solution was filtered to remove
nonincorporated drugs. Blank NPs were produced in the
same manner without adding Sal.
Size and zeta potential analysis of the NPs
Mean diameter and size distribution were measured by
photon correlation spectroscopy (DLS) with a Brookha-
ven BI-9000AT instrument (Brookhaven Instruments
Corporation, Holtsville, NY, USA). Zeta potential was
measured by the laser Doppler anemometry (Zeta Plus,
Zeta Potential Analyzer, Brookhaven Instruments Cor-
poration, USA). All measurements were performed at
25°C. The values were calculated from the measure-
ments performed at least in triplicate.
Morphology studies
Morphological examination of the NPs was conducted
using a JEM-100S transmission electron microscope
(TEM, JEOL Ltd., Akishima-shi, Japan). One drop of NP
suspension was placed on a copper grid covered with
nitrocellulose membrane and air-dried before observation.
Drug loading content and encapsulation efficiency
To determine the Sal-loaded NPs’ drug loading content, 1
mL of the NPs was dried in the oven. Then, Sal was redis-
solved in 3 mL 95% ethanol and centrifuged. The super-
natant derivatized with vanillin (Accelerating Scientific
and Industrial Development thereby Serving Humanity,
Shanghai, China) in an acidic medium at 72°C for 40
min. The derivatization mixture was determined by the
ultraviolet absorption at the wavelength of 527 nm, a
strong absorption band of Sal with reference to a cali-
bration curve on a Shimadzu UV3100 spectrophotom-
eter (Shimadzu, Hadano, Japan).Drug loading content and encapsulation efficiency were
obtained by the following equations:
Drug loading content %ð Þ
¼ Weight of the drug in nanoparticles
Weight of the nanoparticles
 100%
Encapsulation efficiency %ð Þ
¼ Weight of the drug in nanoparticles
Weight of the feeding drug
 100%
Stability evaluation
Sal-loaded NPs and blank NPs were kept at room temperature.
Particle sizes were determined by DLS every 2 days for 15
days to evaluate stability.
In vitro release of Sal-loaded NPs
In vitro release of Sal from NPs was investigated by a
dialysis method. Briefly, a volume of 1 mL NP solution
was sealed in the dialysis bag (molecular weight cutoff
14,000 Da). The dialysis bag was immersed into a 5-mL
0.01 M pH 7.4 PBS solution containing 0.5% Tween 80
at 37°C in a constant temperature shaker. At predeter-
mined time points, aliquots were withdrawn from the
beaker and replaced with equal volume of the media.
The Sal content in the release medium was determined
by pre-HPLC (derivatized with 2,4-dinitrophenol (DNP,
Accelerating Scientific and Industrial Development thereby
Serving Humanity, Shanghai, China) in an acidic medium
at 55°C for 30 min in a C18 column (Agilent Technologies,
Ltd., Santa Clara, CA, USA), with the mobile phase con-
sisting of methanol:1.5% aqueous acetic acid = 93:7, the
flow rate of 1 mL/min, the column temperature of 25°C,
the injection volume of 20 μL, and the detector at a wave-
length of 392 nm). All the experiments met the sink condi-
tion and were repeated in triplicate.
In vivo safety studies of Sal-loaded SE-NPs
All animal studies were performed in compliance with
guidelines set by the Animal Care Committee at Drum
Tower Hospital, Nanjing, China. 8BC nudes (18 to 22 g,
4 to 5 weeks, male, Animal Care Committee at Drum
Tower Hospital, Nanjing, China) were embedded with
1 × 1-cm tumor pieces subcutaneously on the right ax-
illa. Tumor dimensions were measured with vernier cali-
pers, and the volumes were calculated as follows: Tumor
volume (mm3) =Width2 × Length / 2. When the tumors
reached 100 mm3 (designated as day 1), the animals were
randomized into the following treatment groups: free Sal
(4 mg/kg), free Sal (8 mg/kg), and Sal NPs prepared by the
single emulsion method (SE-NPs) (8 mg/mL). The num-
ber of surviving mice was counted to preliminarily evalu-
ate the safety of Sal SE-NPs in vivo.
Figure 1 1H nuclear magnetic resonance spectra (300 MHz, 25 μC) of PEG-Pep-PCL in CDCl3.
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Statistical analyses of data were done using Student's t test.
The data are listed as mean ± SD, and values of P < 0.05
were accepted as a statistically significant difference.
Results and discussion
Copolymer synthesis and characterization
The mPEG-Pep-PCL copolymers were synthesized as
described in the ‘Methods’ section. Figure 1 shows the
1H NMR spectra of mPEG-Pep-PCL copolymers inFigure 2 The stability of NPs with different concentrations of F68.trichloromethane (CDCl3), indicating that the peptide
was successfully conjugated into the copolymer. The
mole ratio of hydrophilic block to hydrophobic block
(mPEG/PCL) in mPEG-Pep-PCL copolymer was about
0.63 based on the integral ratio of -CH2-O- (4.044 ppm) in
PCL segment to -CH2-CH2-O (3.5 ppm) in mPEG segment
from 1H NMR measurement. Thus, the number-average
molecular weight (Mn) of the resulting mPEG-Pep-PCL
copolymer was determined to be approximately 24,038
(Figure 1).
Table 1 The diameter and polydispersity of NPs prepared
by different methods
Nanoparticles Diameter (nm) Polydispersity
Sal-loaded SE-NPs 235.8 ± 1.9 0.160 ± 0.028
Blank SE-NPs 224.1 ± 7.5 0.166 ± 0.005
Sal-loaded NR-NPs 151.1 ± 1.1 0.099 ± 0.041
Blank NR-NPs 148.1 ± 2.9 0.11 ± 0.015
Sal, salinomycin; SE-NPs, nanoparticles prepared by single emulsion method;
NR-NPs, nanoparticles prepared by nanoprecipitation method.
Wang et al. Nanoscale Research Letters 2014, 9:351 Page 5 of 9
http://www.nanoscalereslett.com/content/9/1/351Determination study of the surfactant concentration
In the nanoprecipitation method, the surfactant is not
really involved in the formation of NPs; it acts as a
stabilizer keeping the particles' stability. It was found that
a fourfold increase of the size was observed for the parti-
cles without surfactant. Instead, only small variations in
size were observed in 2 months for those prepared with
the surfactant [37]. Nevertheless, there were no studies
about the relationship between the concentration of F68
and NP stability. In our study, four proportions were tried
and the results are listed in Figure 2. According to theFigure 3 The TEM images of Sal NPs prepared by different methods.results, the stability of NPs increased in accordance with
the increase of F68 concentration, and when the F68 pro-
portion was 1%, the optimal NP formulation was obtained
with the smallest particle size (mean particle size about
137.56 nm) and a more stabilized property. Based on this
screening, 1% turned out to be the best proportion for NP
suspensions.
Size and morphology studies of NPs prepared by the two
methods
The particle size and size distribution of these four NPs
in aqueous solution were determined by DLS, and the
results are displayed in Table 1. As we can see, the par-
ticle sizes of the NPs prepared by the nanoprecipitation
method (NR-NPs) and SE-NPs were approximately 150
and 230 nm, respectively. However, there was no signifi-
cant difference in the particle size between the blank
NPs and the Sal-loaded NPs (data not shown). This
might be because the hydrophobic drug of Sal can be
well encapsulated and equally distributed in the hydro-
phobic core of the NPs [38-40]. As shown in Figure 3,
TEM depicted the shape of NPs prepared by these two
Table 2 The drug loading content and encapsulation





Sal-loaded SE-NPs 89.70 ± 5.7 8.12 ± 5.7
Sal-loaded NR-NPs 81.51 ± 8.9 7.40 ± 8.9
Sal, salinomycin; SE-NPs, nanoparticles prepared by single emulsion method;
NR-NPs, nanoparticles prepared by nanoprecipitation method.
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NR-NP and SE-NP also exhibited a spherical shape com-
pared with the Sal-loaded NR-NP and SE-NP. We can
distinguish the dark area in Sal-loaded NR-NP and SE-
NP. This result helped us to deduce that Sal has been
encapsulated into the NPs. The diameter observed by
TEM was smaller than that detected on the Zetasizer
Nano ZS Analyzer by DLS technique. There is a reason
that the diameter of the NPs obtained by DLS reflected
the hydrodynamic diameter of NPs swelling in water, while
that observed by TEM was the diameter of dried NPs.
Drug loading content and encapsulation efficiency
The results of Sal encapsulation levels are shown in
Table 2. SE-NPs exhibited higher entrapment efficiency
than NR-NPs; this just corresponds to the results con-
firmed by several researchers [41,42]. We thought that
this may be due to the larger size of SE-NP than NR-NP
which could support a larger space for Sal encapsulation.
In addition to this, the lower encapsulation efficiency of
NR-NPs may partially be ascribed to the residue surfac-
tant molecules on the particle surface, which were not
washed away [43].Figure 4 The stability of SE-NPs and NR-NPs.Stability evaluation
Figure 4 shows the particle size change of NR-NPs and
SE-NPs within 15 days [44,45]. During this period, the
particle size of SE-NPs increased slightly. The particle
size of NR-NPs with or without Sal existed with a large
diameter in day 12; however, there were no obvious dif-
ferences between the Sal-loaded NPs and blank NPs pre-
pared by the nanoprecipitation method. Besides this, the
particle size of NR-NPs decreased after 6 days in our
observation. We consider that this may be because the
NR-NPs were not stable enough; thus, most of the larger
NPs aggregated, and the smaller NPs showed a decreased
particle size. This result indicates that SE-NPs showed a
better stability.
In vitro release of Sal-loaded NPs
To study the release behavior of Sal in vitro, SE-NPs and
NR-NPs were incubated in a dialysis bag under shaking
at 37°C, and the released Sal was quantified using pre-
HPLC. Figure 5 shows the cumulative in vitro release of
Sal from the two kinds of NPs. All NPs exhibited a fast
release of Sal at the initial stage and a sustained release
in the following time. NPs prepared by the nanoprecipi-
tation method presented a more prominent burst release
(approximately 56% at the first 4 h and 89% at the first
24 h). The release pattern of NPs prepared by the single
emulsion method was more sustainable with a smaller
initial burst rate (approximately 45% at the first 4 h and
70% at the first 24 h). This result may be due to the NR-
NPs with the smaller particle size and surfactant mole-
cules on the particle surface. In addition, Sal appeared to
be released from Sal-loaded NPs in a biphasic way, that
is, the release profile can be roughly divided into two
Figure 5 The release curve of Sal from SE-NPs and NR-NPs. Sal, salinomycin; NPs, nanoparticles; F68, poloxamer 188; SE-NPs, nanoparticles
prepared by single emulsion method; NR-NPs, nanoparticles prepared by nanoprecipitation method.
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considered as an initial burst, and the second phase
showing sustained release for up to 96 h took place after
this initial effect in which Sal was released.
Primary toxicity observation of Sal-loaded SE-NPs
The number of living mice after injection with free Sal
and Sal-loaded SE-NPs is shown in Table 3. According
to the data that we collected, the mice died immediately
after injection with free Sal (8 mg/kg). When half of the
dose (4 mg/kg) was used, the mice did not die after in-
jection. However, most of them died in the next day, and
the number of viable mice was 2. Interestingly, when
injected with Sal-loaded SE-NPs (8 mg/kg), none of the
mice died in our observation period. Therefore, it was
verified that encapsulating Sal into SE-NPs can reduce
its side effects .The possible reasons for this are that (a)
SE-NPs can target Sal delivery to tumor tissue which
can increase the tumor's drug concentration and de-
crease drug concentration of normal tissues and (b) sus-
tained release can keep the normal tissues out of lethal
threshold.Table 3 The number of live nude mice after injection with
different drugs and dosages
Day 0 Day 1 Day 2 Day 10
Free sal (8 mg/kg) 0 0 0 0
Free sal (4 mg/kg) 5 2 1 1
Sal-loaded SE-NPs (8 mg/kg) 4 4 4 4
Sal, salinomycin; SE-NPs, nanoparticles prepared by single emulsion method.
Five mice in each group.Conclusions
In this paper, we used the PEG-Pep-PCL NPs, which have
been proven effective for targeting tumor tissue specific-
ally, to improve drug efficacy and reduce Sal-caused
adverse effects. To determine the optimum method for
Sal-loaded NP preparation, we made a comparison be-
tween NR-NPs prepared with different proportions of F68.
Besides, we compared the physiochemical traits of NR-
NPs and SE-NPs. Based on the results of our study, we
confirmed that 1% is the best proportion of F68 for NR-
NP preparation, due to the best stability of NR-NPs pre-
pared with 1% of F68, and the SE-NPs showed superior
stability, higher drug loading efficiency, and more sustain-
able but complete release, which means that the single
emulsion method is better for Sal-loaded NP formulation.
Preliminary toxicity observation indicated a striking higher
survival rate of mice injected with Sal-loaded SE-NPs,
which means that entrapping Sal into SE-NPs can greatly
reduce its adverse effects. For consideration of the physical
traits and in vivo animal study, we conclude here that
SE-NPs prepared in this study have a high potential to be
used for Sal delivery.Abbreviations
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